Share on StockTwits

Analysts at HC Wainwright boosted their target price on shares of Epizyme (NASDAQ:EPZM) from $40.00 to $45.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 28.50% from the stock’s previous close.

Epizyme (NASDAQ:EPZM) opened at 35.02 on Wednesday. Epizyme has a 52-week low of $18.10 and a 52-week high of $42.71. The stock has a 50-day moving average of $31.27 and a 200-day moving average of $27.05. The company’s market cap is $1.152 billion.

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Epizyme from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 7th. They now have a $36.80 price target on the stock. Analysts at Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday, July 15th. They set a “buy” rating and a $40.00 price target on the stock.

In other Epizyme news, EVP Robert A. Copeland sold 20,000 shares of Epizyme stock on the open market in a transaction dated Monday, August 4th. The stock was sold at an average price of $29.42, for a total value of $588,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.